[go: up one dir, main page]

DK0649425T3 - Pyridino-, pyrrolidino- og azepino-substituerede oximer, som er anvendelige som anti-atherosklerose- og anti-hypercholester - Google Patents

Pyridino-, pyrrolidino- og azepino-substituerede oximer, som er anvendelige som anti-atherosklerose- og anti-hypercholester

Info

Publication number
DK0649425T3
DK0649425T3 DK93912362T DK93912362T DK0649425T3 DK 0649425 T3 DK0649425 T3 DK 0649425T3 DK 93912362 T DK93912362 T DK 93912362T DK 93912362 T DK93912362 T DK 93912362T DK 0649425 T3 DK0649425 T3 DK 0649425T3
Authority
DK
Denmark
Prior art keywords
atherosclerosis
substituted
oxymers
hypercholester
azepino
Prior art date
Application number
DK93912362T
Other languages
English (en)
Inventor
Charles H Spilman
Scott D Larsen
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of DK0649425T3 publication Critical patent/DK0649425T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK93912362T 1992-06-17 1993-05-05 Pyridino-, pyrrolidino- og azepino-substituerede oximer, som er anvendelige som anti-atherosklerose- og anti-hypercholester DK0649425T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90022992A 1992-06-17 1992-06-17
PCT/US1993/004059 WO1993025553A1 (en) 1992-06-17 1993-05-05 Pyridino-, pyrrolidino- and azepino-substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents

Publications (1)

Publication Number Publication Date
DK0649425T3 true DK0649425T3 (da) 1999-09-27

Family

ID=25412199

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93912362T DK0649425T3 (da) 1992-06-17 1993-05-05 Pyridino-, pyrrolidino- og azepino-substituerede oximer, som er anvendelige som anti-atherosklerose- og anti-hypercholester

Country Status (13)

Country Link
US (3) US5565468A (da)
EP (1) EP0649425B1 (da)
JP (1) JPH07507796A (da)
CN (1) CN1081678A (da)
AT (1) ATE177426T1 (da)
AU (1) AU4293393A (da)
DE (1) DE69323883T2 (da)
DK (1) DK0649425T3 (da)
ES (1) ES2130269T3 (da)
GR (1) GR3029946T3 (da)
IL (1) IL105693A0 (da)
MX (1) MX9303594A (da)
WO (1) WO1993025553A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
RU2308457C2 (ru) * 2001-04-27 2007-10-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Пиразоло [1, 5-а] пиридины и содержащие их лекарственные средства
ES2289116T3 (es) * 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
JP4322211B2 (ja) * 2002-10-22 2009-08-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 7−フェニルピラゾロピリジン化合物
US7176216B2 (en) * 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
WO2007008529A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
WO2008005908A2 (en) 2006-07-07 2008-01-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
EP2176260A1 (en) * 2007-07-11 2010-04-21 Auckland Uniservices Limited Pyrazolo[1,5-a]pyridines and their use in cancer therapy
NZ588376A (en) * 2008-04-15 2011-06-30 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound having antagonism against corticotropin-releasing factor (CRF) receptor
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
WO2011043387A1 (ja) * 2009-10-08 2011-04-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
CN103980281B (zh) * 2014-05-27 2016-06-08 天津市斯芬克司药物研发有限公司 一种咪唑吡嗪化合物及其制备方法
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
MX373154B (es) 2015-04-03 2020-04-22 Incyte Holdings Corp Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
UA125559C2 (uk) 2016-04-22 2022-04-20 Інсайт Корпорейшн Композиції інгібітора lsd1
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1600969A (en) * 1977-01-07 1981-10-21 Acf Chemiefarma Nv Heterocyclic compounds
US4352804A (en) * 1978-07-25 1982-10-05 Acf Chemiefarma Nv Oxime ethers, their preparation and pharmaceutical compositions containing them
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines

Also Published As

Publication number Publication date
US5597816A (en) 1997-01-28
US5565468A (en) 1996-10-15
MX9303594A (es) 1994-01-31
WO1993025553A1 (en) 1993-12-23
EP0649425A1 (en) 1995-04-26
DE69323883D1 (de) 1999-04-15
GR3029946T3 (en) 1999-07-30
ES2130269T3 (es) 1999-07-01
US5523318A (en) 1996-06-04
ATE177426T1 (de) 1999-03-15
CN1081678A (zh) 1994-02-09
IL105693A0 (en) 1993-09-22
EP0649425B1 (en) 1999-03-10
JPH07507796A (ja) 1995-08-31
DE69323883T2 (de) 1999-07-22
AU4293393A (en) 1994-01-04

Similar Documents

Publication Publication Date Title
DK0649425T3 (da) Pyridino-, pyrrolidino- og azepino-substituerede oximer, som er anvendelige som anti-atherosklerose- og anti-hypercholester
MX9302214A (es) Derivados de taxol y proceso para su preparacion
CA2160966A1 (fr) Derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IS4185A (is) Hliðstæð aðferð til framleiðslu fenýlsúlfonylamino-pýrimidines afleiða
ATE167476T1 (de) Substituierte 2-phenyl-3-methocypropensäurenester als fungizide mittel.
ES2195970T3 (es) L-ribavirina y usos de la misma.
DE122004000025I1 (de) Borons{ure-und-Esterverbindungen, deren Systhese und Verwendungen.
ATE126215T1 (de) Anti-entzündende 4-aminophenol-derivate.
PT688789E (pt) Processo de lipopeptideos processo para a sua preparacao e sua utilizacao
ITMI931780A1 (it) Tropil 7-azaindolil-3-carbossiamidi
GB9003939D0 (en) Sulphatase inhibitors
NO944406L (no) Nye 7 e inhibitorer
NO934706L (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
GR3015836T3 (en) Sulphonylbenzyl substituted benzo- and pyridopyridones.
DE59103696D1 (de) Biomasse zur produktion von virus/virusantigen.
BG100248A (bg) Инхибитори на скваленсинтетаза
TR199701298T1 (xx) Tetralinler.
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
SE9402241D0 (sv) Inhibitor
AU5994696A (en) Modified alpha-d-glcp-(1-2)-alpha-d-glcp-(1-3)-alpha-d-glcp- analogues
FI963785A0 (fi) Hypokolesteroleemisia, antiateroskleroottisia ja hypotriglyserideemisiä merkaptoasetyyliamidijohdannaisia
BR9407232A (pt) Compostos de tiocarbamoíla
MX9800053A (es) Herbicidas de cis-2,3-expoxicicloalcanol bencilado.
RU1809521C (ru) Генератор плазмы
AU8497191A (en) Compositions and methods for treating hiv infections